[Adipose tissue renin-angiotensin system in obese]

Abstract

Activation of the renin-angiotensin system (RAS) is commonly observed in patients with obesity. Adipose tissue expresses all components of RAS, implicating adipose renin-angiotensin system (A-RAS) in the pathophysiology of obesity. Angiotensin-converting enzyme(ACE) inhibitors and angiotensin II type 1 receptor (AT1R) blockers ameliorate obesity-related metabolic derangement. Of note, CASE-J trial demonstrated that a systemic blockade of RAS significantly reduced the incidence of newly occurring type 2 diabetes, notably in obese patients with hypertension. We reported that adipose tissue-derived AGT is substantially augmented in obesity and may contribute to hypertension in humans, thereby highlighting a pivotal role of A-RAS in systemic RAS activation and resultant metabolic derangement.